Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 8 - Aug 13
Lower bioavailability than injection
My Clinical Lens Have I used it
FOXO4-DRI represents a peptide-based senolytic approach that is more targeted than small-molecule senolytics like dasatinib plus quercetin, which affect broader cellular pathways
People interested in EpitalON typically include: Those exploring peptide bioregulators as part of a broader approach to healthy ageing Biohackers and longevity enthusiasts familiar with Khavinson's research Individuals interested in circadian rhythm support People already using other YourProtocol peptides Important cautions: EpitalON should not be used by anyone under 18 years of age, pregnant or breastfeeding women, or those on medication without consulting their healthcare practitioner
Lipids in Health and Disease, 17 (1), 123
Current Pharmaceutical Design , 16(10), 12241232
US$ 28.78
US$ 29.28
US$ 22.84
